Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Epirubicin|DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Trastuzumab
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Collaborators: Amgen|Ebewe Pharma GmbH|Hoffmann-La Roche|Sanofi